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bCharité – Universitätsmedizin Berlin, Experimental and Clinical Research Center, Berlin, Germany
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Abstract.
Background: Depressive symptoms often co-occur with Alzheimer’s disease (AD) and can impact neuropsychological test
results. In early stages of AD, disentangling cognitive impairments due to depression from those due to neurodegeneration
often poses a challenge.
Objective: We aimed to identify neuropsychological tests able to detect AD-typical pathology while taking into account
varying degrees of depressive symptoms.
Methods: A battery of neuropsychological tests (CERAD-NP) and the Geriatric Depression Scale (GDS) were assessed, and
cerebrospinal fluid (CSF) biomarkers were obtained. After stratifying patients into CSF positive or negative and into low,
moderate, or high GDS score groups, sensitivity and specificity and area under the curve (AUC) were calculated for each
subtest.
Results: 497 participants were included in the analyses. In patients with low GDS scores (≤10), the highest AUC (0.72)
was achieved by Mini-Mental State Examination, followed by Constructional Praxis Recall and Wordlist Total Recall
(AUC = 0.714, both). In patients with moderate (11–20) and high (≥21) GDS scores, Trail Making Test-B (TMT-B) revealed
the highest AUCs with 0.77 and 0.82, respectively.
Conclusion: Neuropsychological tests showing AD-typical pathology in participants with low GDS scores are in-line with
previous results. In patients with higher GDS scores, TMT-B showed the best discrimination. This indicates the need to focus
on executive function rather than on memory task results in depressed patients to explore a risk for AD.
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INTRODUCTION
Cognitive impairments in old age may occur as
the core symptoms of early dementia due to Alzhei-
mer’s disease (AD) [1], or they may accompany an
episode of major depression (MDE) [2]. Currently,
various hypotheses aiming to clarify the interrelation
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between depression and AD exist. For example, hav-
ing a history of depression has been found to increase
one’s risk of developing AD [3]. Depression in old
age has also been suggested to represent a prodromal
stage of AD rather than a risk factor for AD [1, 4, 5].
In clinical practice with geriatric patients, depressive
symptoms and cognitive impairments often co-occur
[6]. This makes it difficult to differentiate whether
cognitive impairments are caused by depression or
whether they manifest as part of a syndrome caused
by AD.
There are various methods available to obtain evi-
dence for an underlying AD pathology in cognitively
impaired patients, the more biomarkers and further
clinical information are available to be combined,
the more accurate the diagnosis [7]. Different kinds
of biomarkers help to identify the neuropathologi-
cal substrates and etiology of cognitive impairments.
An important source of information in the diagnosis
of AD are brain magnetic resonance imaging (MRI)
scans [8]. However, MRI scans can be contraindi-
cated due to pacemakers or other electrical implants,
anxiety, or economic reasons.
The quantification of total-Tau (t-Tau) and amy-
loid- 1-42 (A42) proteins in the cerebrospinal fluid
(CSF) have been established to detect early AD-
typical pathology with high sensitivity and specificity
[9]. Specialized memory clinics may recommend the
quantification of CSF biomarkers in late-life depres-
sion to help determine whether an underlying AD
pathology exists [10]. However, lumbar punctures for
obtaining CSF might be perceived as highly invasive
by some patients. Furthermore, processing and ana-
lyzing CSF is highly demanding and alterations in
sample processing can lead to varying results [11].
Lastly, lumbar punctures might be contraindicated in
some patients taking anticoagulants or suffering from
conditions like scoliosis.
Neuropsychological assessments together with
clinical information is the basis to determine dif-
ferent stages of cognitive decline [12, 13]. Ideally,
as much additional diagnostic evidence as possible
should be used to accurately diagnose AD [7]. How-
ever, for different reasons mentioned earlier, some
methods might not be available. Thus, identifying
easy to conduct, sensitive, and valid neuropsycho-
logical tests can add to a more accurate diagnosis of
underlying AD pathology.
Previous studies have aimed to identify neuropsy-
chological tests able to differentiate between early
AD and late-onset depression. There is evidence that
the meaningfulness of psychological test results can
differ depending on the affective state of patients [14,
15], which should be considered when interpreting
test results. A frequently cited test helpful in dis-
tinguishing cognitive impairments due to depression
from those due to AD is the Clock Drawing Test (CDT
[16]), although contradictory findings exist regard-
ing the extent to which the CDT is able to fulfill
this task [17, 18]. When examining episodic mem-
ory function, both patients with early AD and MDE
show a below-average performance on immediate
and delayed recall tests. However, depressed patients
retain the learned information better than early AD
patients, as measured by recognition tasks [19].
Moreover, there is evidence that depression in AD
patients additionally impairs performance in execu-
tive function tasks as measured by the Trail Making
Test Part B (TMT-B) compared to AD patients with-
out depression [20].
Many publications address the differences in
cognitive domains between depression and AD. How-
ever, depression is not black or white, but rather
there are varying stages in affective mood between
clinically depressed and non-depressed. Taking these
considerations into account, we aimed to examine the
effect of varying numbers of depressive symptoms
when interpreting neuropsychological results. In our
approach, we wanted to examine the value of different
neuropsychological tests to detect AD-typical pathol-
ogy in old age CSF classified patients. We hypoth-
esized that depending on the number of depressive
symptoms patients present, neuropsychological tests
would vary in their ability to differentiate between
patients with and without AD-typical changes in CSF.
METHODS
Participants
The sample consisted of memory clinic patients
presenting with subjective cognitive impairment
between 2007 and 2018. Routine clinical practice
comprised of a medical case history assessment, psy-
chopathological examination, comprehensive neu-
ropsychological testing, cranial imaging, and a
lumbar puncture to assess CSF biomarkers (A40,
A42, and t-Tau). DSM-IV/-V diagnosis for each
patient was reached by a consensus panel. The study
was conducted in accordance with the Declaration of
Helsinki. Ethical vote was obtained from the Ethics
Committee of the Charité Universitätsmedizin Berlin,
vote number EA4/057/20.
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Neuropsychological tests and clinical scales
We assessed cognitive performance with the Con-
sortium to establish a registry for Alzheimer’s dis-
ease neuropsychological test battery (CERAD-NP).
CERAD-NP is a standardized instrument used in rou-
tine clinical practice to assess and stage AD-typical
cognitive impairments [13].
Specifically, the CERAD-NP consists of the Mini-
Mental State Examination (MMSE) [21], phonemic
fluency, and visual naming (Boston Naming Test
[22]), tests for constructional praxis and construc-
tional praxis delayed recall and verbal memory tasks.
Furthermore, tests to measure processing speed and
executive function, namely the Trail Making Test A
(TMT-A) and the TMT-B [23], as well as the CDT
[16] were performed. Results on each CERAD-NP-
subscale are z-standardized, taking gender, age, and
years of education into account.
Depressive symptoms were assessed with the orig-
inal 30-item version of the Geriatric Depression Scale
(GDS; yes/no dichotomous scale, range 0–30, scores
proportional to depressive symptoms) [24]. The GDS
is a self-administered questionnaire shown to be a
valid instrument to help identify late-life depression
[25]. A cut-off score of ≥11 can be seen as a possible
indicator of depression, as it has been shown to have a
sensitivity of 84% and a specificity of 95% for accu-
rately detecting late-life depression [26]. According
to our clinical experience, GDS scores of 21 or higher
are highly indicative of clinical depression. For these
reasons, we decided to divide patients into one of
three GDS subgroups, namely patients with a GDS-
score ≤10 (low GDS), 11–20 (moderate GDS), and
≥21 (high GDS).
Cerebrospinal fluid
CSF was collected and analyzed according to a
standardized protocol described in detail elsewhere
[27]. As it is known that differing and analytical
procedures and lot-to-lot variation of analytical kits
can strongly influence CSF biomarkers [28], we
established the following CSF biomarker cut-offs as
indicative of AD-typical pathology in our memory
clinic: A42 ≤ 600 pg/ml (sensitivity 0.82, specificity
0.80) or ratio A42/A40 ≤ 0.065 (sensitivity 0.80,
specificity 0.75), added by t-Tau ≥ 350 pg/ml (sensi-
tivity 0.74, specificity 0.78).
Following the NIA-AA research framework
[29], we defined CSF positive patients showing
both amyloid-pathology (A+) and neurodegeneration
(N+). For the analyses presented here, we defined
patients as having AD-typical pathology (i.e.,
CSF-positive) when t-Tau ≥350 pg/ml and A42
≤ 600 pg/ml. In CSF negative patients, the cut-offs
were t-Tau < 350 pg/ml and A42 > 600 pg/ml, corre-
sponding to A- and N-.
Inclusion and exclusion criteria
We included patients that underwent a com-
plete diagnostic assessment in our memory clinic as
described above and who had an MMSE score of 24
or higher with the aim to identify patients with mild
or no objective cognitive deficits.
We excluded patients that did not fulfill our estab-
lished CSF positive or CSF negative criteria. No
further exclusion criteria (e.g., diagnosis or medica-
tion) were defined in order to better reflect a cohort
of patients clinicians face in their everyday work.
Statistical analyses
Data were analyzed using the statistical software
“R”, version 3.2.4. The authors were blind to patients’
diagnosis.
After dividing patients into CSF positive and CSF
negative, a single value classification was perfor-
med. We calculated receiver operating characteris-
tic (ROC) curves for all neuropsychological tests by
calculating the sensitivity and specificity for each
value of the neuropsychological test results. The per-
formance of the classification was assessed using
the area under the curve (AUC). The AUC typically
ranges between 0.5 and 1, with an AUC of 1 indicating
perfect discrimination and an AUC of 0.5 reflect-
ing a random classification. Confidence intervals and
p-values to compare ROC curves were calculated
according to the Delong algorithm.
For further analyses, we formed the cognitive
domains Recall (Wordlist Recall, Constructional
Praxis Savings, Discriminability) and Executive
Function (Semantic Fluency, Trail Making Test A and
B) and calculated AUC values as described above.
To investigate the relation between classification
performance and depressive symptoms, we per-
formed a series of single value classifications for
patients with increasing GDS scores. For a given GDS
score, we selected all patients with a score of ±10 and
performed the single value classification as described
above.
For the descriptive statistics, Student’s t-tests
or when appropriate non-parametric Wilcoxon
822 F. Menne et al. / Neuropsychological Tests to Identify AD
Table 1





Female sex (%) 53 44 0.15
Years of education 13.4 ± 3.0 13.6 ± 2.9 0.61
Age 68.0 ± 9.0 69.8 ± 9.9 0.61
t-Tau (pg/ml) 549 ± 284 228 ± 65 <0.001
A42 (pg/ml) 391 ± 115 1054 ± 339 <0.001
Ratio t-Tau/A42 1.52 ± 0.96 0.24 ± 0.10 <0.001
MMSE 26.4 ± 1.7 27.7 ± 1.6 <0.001
Mean GDS subgroup
0–10 (n = 214)
5.8 ± 2.7 6.0 ± 2.9 0.8
Mean GDS subgroup
11–20 (n = 197)
14.7 ± 2.8 14.9 ± 2.9 1.0
Mean GDS subgroup
21–30 (n = 86)
23.7 ± 2.6 24.1 ± 2.6 1.0
two-sample tests were used to investigate differences
between group means on continuous variables.
RESULTS
Patient selection
A total of 2,101 patients underwent a complete
diagnostic assessment at our memory clinic between
2007 and 2018. A total of 1,414 patients with an
MMSE score of < 24 were excluded from further
analyses.
Patient characteristics
Of the remaining 687 patients, 190 had CSF
biomarker results that did not fulfill criteria for either
being CSF positive (A + and N+) or CSF negative
(A- and N-) and were excluded from further analy-
ses. Of the remaining 497 patients, 307 were defined
as being CSF negative and 190 as CSF positive.
Table 1 provides information on patients’ demo-
graphics, MMSE, GDS, and CSF data.
The 190 CSF positive patients performed signif-
icantly worse in all CERAD-NP subtests than CSF
negative patients. CSF positive patients scored lower
than –1.5 SD below the mean in Constructional Praxis
Recall (–1.8 ± 1.3), World List Trial 3 (–1.7 ± 1.5),
Wordlist Recall (–1.7 ± 1.4), and Wordlist Total
(–1.8 ± 1.5) tests. CSF negative patients yielded
z-scores ≥–1.5 SD in all CERAD-NP subtests, indi-
cating normative cognitive performance. Table 2
shows the complete list of neuropsychological test




BNT –0.1 ± 1.3 0.2 ± 1.2 <0.001
CDT 2.2 ± 1.0 1.6 ± 0.9 <0.001
CP –0.2 ± 1.3 0.1 ± 1.2 <0.05
CPR –1.8 ± 1.3 –0.4 ± 1.6 <0.001
CPS –1.5 ± 1.3 –0.4 ± 1.2 <0.001
MMSE 26.4 ± 1.7 27.7 ± 1.6 <0.001
SF –0.9 ± 1.1 –0.4 ± 1.3 <0.001
TMT-A –0.8 ± 1.3 0 ± 1.4 <0.001
TMT-B –1.2 ± 1.3 0 ± 1.7 <0.001
TMT-B/A –0.6 ± 1.1 –0.1 ± 1.3 <0.001
WL discr –1.3 ± 1.4 –0.5 ± 1.4 <0.001
WL I –0.8 ± 1.3 –0.2 ± 1.1 <0.001
WL R –1.7 ± 1.4 –0.6 ± 1.2 <0.001
WL S –1.4 ± 2.2 –0.4 ± 1.8 <0.001
WL total –1.8 ± 1.5 –0.7 ± 1.4 <0.001
WL1 –1.2 ± 1.2 –0.5 ± 1.2 <0.001
WL2 –1.4 ± 1.3 –0.6 ± 1.3 <0.001
WL3 –1.7 ± 1.5 –0.6 ± 1.4 <0.001
MMSE and CDT mean raw scores as well as CERAD-NP mean z-
standardized scores in the groups of CSF-positives and -negatives
(sorted alphabetically). BNT, Boston Naming Test; CDT, Clock
Drawing Test. CP: Constructional Praxis; CPR, Constructional
Praxis Recall; CPS, Constructional Praxis Savings; MMSE, Mini-
Mental Status Examination; SF, Semantic Fluency; TMT-A, Trail-
Making Test A; TMT-B, Trail-Making Test B; TMT-B/A, Ratio
of TMT B/A; WL discr, Wordlist Discrimination; WL I, Wordlist
Intrusions; WL R, Wordlist Delayed Recall; WL S, Wordlist Sav-
ings; WL total, Wordlist Total of immediately recalled words;
WL 1, Wordlist 1st trial; WL 2, Wordlist 2nd trial; WL 3, Wordlist
3rd trial. All group differences showed significance.
Patient characteristics by GDS subgroup
In patients with low GDS scores (≤10, n = 214),
102 were CSF positive (47%). In those with mod-
erate GDS scores (11–20, n = 197), 73 were CSF
positive (37%), and in those with high GDS scores
(≥21, n = 86), 15 were CSF positive (17%).
Discrimination accuracy of neuropsychological
tests between CSF groups and GDS
subgroups
In patients with GDS scores ≤10, the neuropsy-
chological tests with the highest specificity and
sensitivity in differentiating between CSF positive
and CSF negative were the MMSE (AUC = 0.72),
Constructional Praxis Recall (0.71), and Wordlist
Total (0.71). In patients with GDS scores between
11–20, the Trail Making Test-B (0.77), Wordlist
Discriminability (0.75), and Wordlist Recall (0.75)
showed the highest specificity and sensitivity. The
neuropsychological tests with the highest specificity
and sensitivity to differentiate between CSF groups
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AUC of neuropsychological tests
AUC all AUC GDS ≤10 AUC GDS 11–20 AUC GDS 21–30
WL R 0.737 (305/182) [0.69,0.784] 0.706 (112/99) [0.634,0.777] 0.752 (122/69) [0.678,0.826] 0.783 (71/14) [0.659,0.906]
CPR 0.732 (307/190) [0.687,0.778] 0.714 (112/102) [0.644,0.783] 0.733 (124/73) [0.662,0.804] 0.776 (71/15) [0.639,0.912]
CPS 0.728 (306/189) [0.681,0.775] 0.706 (111/102) [0.635,0.777] 0.738 (124/72) [0.666,0.81] 0.733 (71/15) [0.573,0.893]
WL total 0.719 (307/190) [0.673,0.765] 0.714 (112/102) [0.645,0.783] 0.723 (124/73) [0.648,0.798] 0.735 (71/15) [0.587,0.884]
WL 3 0.719 (307/190) [0.672,0.766] 0.705 (112/102) [0.635,0.775] 0.737 (124/73) [0.662,0.811] 0.721 (71/15) [0.565,0.876]
MMSE 0.713 (307/190) [0.667,0.758] 0.72 (112/102) [0.653,0.788] 0.68 (124/73) [0.603,0.756] 0.761 (71/15) [0.634,0.887]
TMT-B 0.708 (307/190) [0.663,0.754] 0.643 (112/102) [0.569,0.717] 0.766 (124/73) [0.7,0.831] 0.816 (71/15) [0.704,0.928]
WL 2 0.68 (307/190) [0.632,0.728] 0.667 (112/102) [0.596,0.739] 0.68 (124/73) [0.601,0.759] 0.751 (71/15) [0.603,0.898]
WL discr 0.677 (307/190) [0.629,0.726] 0.645 (112/102) [0.571,0.72] 0.753 (124/73) [0.684,0.823] 0.592 (71/15) [0.447,0.738]
WL 1 0.673 (307/190) [0.625,0.721] 0.678 (112/102) [0.607,0.749] 0.668 (124/73) [0.589,0.747] 0.671 (71/15) [0.508,0.834]
WL sav 0.669 (304/182) [0.616,0.721] 0.638 (111/99) [0.561,0.715] 0.683 (122/69) [0.597,0.768] 0.752 (71/14) [0.62,0.883]
CDT 0.664 (307/190) [0.618,0.71] 0.633 (112/102) [0.563,0.703] 0.665 (124/73) [0.59,0.739] 0.786 (71/15) [0.67,0.902]
TMT-A 0.639 (307/190) [0.589,0.688] 0.634 (112/102) [0.56,0.708] 0.702 (124/73) [0.628,0.776] 0.619 (71/15) [0.434,0.804]
TMT-B/A 0.63 (307/190) [0.581,0.68] 0.552 (112/102) [0.475,0.63] 0.657 (124/73) [0.581,0.734] 0.762 (71/15) [0.626,0.897]
WL I 0.626 (307/190) [0.574,0.678] 0.627 (112/102) [0.552,0.703] 0.635 (124/73) [0.55,0.719] 0.521 (71/15) [0.352,0.69]
SF 0.622 (302/189) [0.572,0.672] 0.618 (112/101) [0.542,0.694] 0.623 (120/73) [0.544,0.701] 0.641 (70/15) [0.463,0.82]
BNT 0.592 (307/190) [0.54,0.644] 0.553 (112/102) [0.475,0.632] 0.6 (124/73) [0.519,0.682] 0.752 (71/15) [0.608,0.895]
CP 0.556 (307/189) [0.502,0.61] 0.521 (112/102) [0.442,0.6] 0.581 (124/72) [0.493,0.668] 0.581 (71/15) [0.371,0.79]
Area under the curve (AUC) as well as number of subjects (CSF negative/positive) and [confidence interval] of each neuropsychological
test in respective GDS score groups and irrespective of GDS score. WL 1, Wordlist 1st trial; CPR, Constructional Praxis Recall; CPS,
Constructional Praxis Savings; WL 3, Wordlist 3rd trial; WL R, Wordlist Delayed Recall; MMSE, Mini-Mental Status Examination; TMT-
A, Trail-Making Test A; WL I, Wordlist Intrusions; WL S, Wordlist Savings; WL discr, Wordlist Discrimination; WL 2, Wordlist 2nd trial;
CDT, Clock Drawing Test; SF, Semantic Fluency; TMT-B, Trail-Making Test B; WL total, Wordlist Total of immediately recalled words;
TMT-B/A, Ratio of TMT B/A; BNT, Boston Naming Test; CP, Constructional Praxis.
Fig. 1. AUC of selected neuropsychological tests with increas-
ing GDS. TMT-B, Trail-Making Test B; CDT, Clock Drawing
Test; BNT, Boston Naming Test; CPS, Constructional Praxis Sav-
ings; WL R, Wordlist Delayed Recall; MMSE, Mini-Mental Status
Examination.
with GDS scores between 21–30 were the Trail Mak-
ing Test-B (0.82), CDT (0.79), and Wordlist Recall
(0.78) tests. An overview of AUC values for all neu-
ropsychological tests by GDS subgroup is presented
in Table 3.
When analyzing the discriminatory power
throughout GDS scores (0–30), we find a rise in
the AUC values of several neuropsychological tests
with increasing GDS scores. In Fig. 1, we present
six CERAD-NP subtests we selected because of
their significant rise in AUC with increasing GDS
values. In particular, the TMT-B and especially the
Boston Naming Test (BNT) test exhibit a marked
rise in AUC values with higher GDS scores. There
are significant differences when comparing AUCs of
the TMT-B (AUC: 0.64 versus 0.82, p < 0.02) and
the BNT (AUC: 0.55 versus 0.75, p < 0.02) between
the two groups with low (≤10) and high (≥21) GDS
scores.
No significant differences can be found when com-
paring the cognitive domains Recall (AUC: 0.71
versus 0.76, p = 0.52) and Executive Function (AUC:
0.65 versus 0.75, p = 0.23) between high and low
GDS score groups (Supplementary Table 1).
DISCUSSION
Cognitive impairments in old age have numerous
causes. Better understanding the etiology of cognitive
decline is a prerequisite for appropriate treatment.
Here, we explored the sensitivity and specificity of
different neuropsychological tests to identify cogni-
tive impairments typical of AD pathology in the pres-
ence of varying degrees of depressive symptoms in
patients verified for AD-typical CSF biomarkers. Our
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findings support our hypothesis that depending on the
number of depressive symptoms, neuropsychological
tests will vary in their ability to differentiate between
subjects with and without AD-typical changes in
CSF. We found that in subjects with a moderate
to high number of depressive symptoms, assessing
executive function with the TMT-B has the high-
est power to discriminate between CSF-positive and
CSF-negative patients. Furthermore, we observed
an increasing discriminatory power of several
CERAD-NP subtests over the course of rising GDS
scores.
Upon closer examination of different neuropsy-
chological subtests and their ability to discriminate
between CSF-positive and negative subjects, the
CDT showed to be a valuable instrument in patients
with high GDS scores between 21–30. However,
differentiation accuracy was lower in patients with
lower GDS scores. Although the CDT is largely
used to assess AD-typical cognitive impairments
and has shown acceptable sensitivity and specificity
in patients with depression [17], its clinical value
remains controversial. It has also been shown that
the CDT lacks sensitivity in mildly impaired patients
[18] and is not well suited to differentiate between
AD patients and patients suffering from other types
of dementia [30].
The MMSE is known to have limitations in detect-
ing cognitive impairments in early AD [31], which
appears to be mainly due to its ceiling and floor effects
and due to the marked impact of age and education
on test results [32]. Interestingly, our results showed
that the MMSE had the highest power (AUC = 0.72)
in distinguishing between CSF positive and CSF neg-
ative patients in the low GDS subgroup. This is most
likely due to the broad range of cognitive domains
that are covered by the MMSE. However, it seems
that in patients with higher GDS scores, other tests
outperform the MMSE.
The TMT-B test was best at differentiating between
CSF positive and negative patients with moderate
to high GDS scores (11–30). The TMT-B assesses,
among others, executive function, which has been
shown to be impaired not only in mild AD [33] but
also in earlier stages of AD (i.e., MCI due to AD)
[34] and there is evidence the TMT-B may help dis-
tinguish between cognitively healthy controls, AD,
and depressed patients [35, 36]. Our results are in-
line with these previous findings. Hence, we can
confirm the value of testing patients’ executive func-
tion to establish a differential neuropsychological
diagnosis.
Interestingly, with increasing GDS scores, we
observed a broad rise in the AUC values of a few
CERAD-NP subtests. It has been shown before that
comorbid depression influences AD patients’ test per-
formance in the TMT-B [20]. In our data, higher
depressive symptoms in CSF positive patients seem
to more strongly influence test performance than in
CSF negative patients. Since being at risk for AD as
defined by CSF-typical biomarker changes typically
leads to a significant difference in test performance
compared to CSF negative patients [37], a concur-
rent high number of depressive symptoms might lead
to an even more pronounced difference in test perfor-
mance. This can be seen as a “double hit”, resulting in
the higher power of a few neuropsychological tests
to differentiate between the two CSF groups. This
might also explain the difference between the AUCs
of the TMT-A and TMT-B tests. The higher cogni-
tive demand of the TMT-B compared to the TMT-A
test might lead to worse performance in CSF patients
with higher GDS scores compared to CSF negative
patients.
Our findings stress the differential diagnostic value
of specific neuropsychological test results of old
age patients presenting with depressive symptoms.
Indeed, depending on the level of depressive symp-
toms, traditionally used tests like the MMSE and
the CDT showed less power than other tests such as
the TMT-B test in discriminating between patients
with and without AD-typical CSF pathology. There-
fore, for patients presenting to a memory clinic
with suspected or clinically manifest depression, we
recommend focusing on tests that assess executive
function rather than the MMSE, CDT, or verbal
memory tests for higher diagnostic differentiation.
Doing so can help guide clinicians in their deci-
sion of whether further diagnostic measures are
warranted.
We consider the high number of patients with
available CSF data a strength of this analysis. To
the best of our knowledge, we are not aware of
any published data of monocentric databases with a
similar amount of CSF data available. Furthermore,
using patients’ CSF data and neuropsychological test
results rather than their diagnosis reduces the risk
of being biased by their clinical diagnosis when
interpreting our findings. Moreover, few publica-
tions regarding neuropsychological test performance
in early AD patients with moderate or high depres-
sive symptoms are available, as mood disorders are
often exclusion criteria in studies on neurodegenera-
tive disorders.
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The cross-sectional nature of the study may be
seen as a limitation. Since no follow-up examina-
tions were conducted, it remains unclear whether
the observed CSF abnormalities resulted in neu-
ropsychological and GDS score changes or whether
these changes were present before CSF abnormali-
ties. Furthermore, no phosphorylated tau (p-Tau) data
was available, which together with A defines AD
according to the NIA-AA research framework [29].
Moreover, since the GDS is a self-reported mea-
sure, scores might not accurately reflect the severity
of depressive symptoms as would be obtained by a
trained clinician. This may have under- or overes-
timated the actual degree of depressive symptoms
in some patients, which might additionally be influ-
enced by antidepressant or anxiolytic medication.
Lastly, the unequal GDS subgroups and CSF group
sizes limit statistical power, thus results presented
here must be interpreted with caution. These differ-
ences are noticeable especially in the ratio of CSF
positive versus negative subjects in the group of GDS
scores ≥21. This is likely due to the fact that the
majority of our patients presenting with memory con-
cerns who have high GDS scores suffer only from
depression and less likely from an additional under-
lying neurodegenerative process. Furthermore, we
suspect that patients with high GDS scores who at
the same time suffer from a neurodegenerative dis-
ease would be more severely impaired and thus have
an MMSE score below 24, which we excluded in this
study.
Our results support previous studies identifying
neuropsychological tests that more accurately dif-
ferentiate between patients with MCI, mild AD,
or MDE. However, especially in mildly cognitively
impaired individuals, differentiation based on neu-
ropsychological tests alone is difficult [38, 39]. Our
findings strengthen existing results regarding which
neuropsychological tests used in clinical routine prac-
tice are best at differentiating between CSF positive
and CSF negative patients while considering varying
degrees of depressive symptoms.
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